Renal Cell Carcinoma Specialty Channel

News

Belzutifan Improved Survival, Response Among Patients With Advanced Clear-Cell Renal Cell Carcinoma

08/30/2024

According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...

According to results from the...

08/30/2024

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology

News

Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence

04/25/2024

Stephanie Holland

According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...

According to interim analysis...

04/25/2024

Oncology

News

Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence

04/16/2024

Stephanie Holland

According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...

According to results from the...

04/16/2024

Oncology

Quiz

Belzutifan vs Everolimus for Quality of Life of Patients With Advanced Clear Cell Renal Cell Carcinoma

03/21/2024

Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?

Did belzutifan improve the time...

03/21/2024

Oncology

News

Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma

03/11/2024

Allison Casey

A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.

A recent study found the use of...

03/11/2024

Oncology

News

Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma

03/11/2024

Allison Casey

According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.

According to a retrospective...

03/11/2024

Oncology

Conference Coverage

Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/27/2024

Thomas Powles , MBBS, MD;

Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.

Thomas Powles, MBBS, MD,...

01/27/2024

Oncology

Conference Coverage

Adjuvant Pembrolizumab Succeeds For Patients With Renal Cell Carcinoma At Increased Risk of Relapse

01/27/2024

Allison Casey ;

Adjuvant pembrolizumab significantly improved overall survival among patients with renal cell carcinoma at an increased risk for recurrence after surgery, when compared with placebo.

Adjuvant pembrolizumab...

01/27/2024

Oncology

Conference Coverage

Adjuvant Nivolumab Failed to Meet End Point for Patients With Renal Cell Carcinoma

01/27/2024

Allison Casey ;

In Part B of CheckMate 914, adjuvant nivolumab monotherapy failed to meet the primary end point of disease-free survival for patients with renal cell carcinoma at high risk of relapse following nephrectomy.

In Part B of CheckMate 914,...

01/27/2024

Oncology

Conference Coverage

Subcutaneous Nivolumab Noninferior to Intravenous Administration Among Patients With Clear Cell Renal Cell Carcinoma

01/27/2024

Saby George , MD;

Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.

Saby George shares insights from...

01/27/2024

Oncology

News

Belzutifan Improved Survival, Response Among Patients With Advanced Clear-Cell Renal Cell Carcinoma

08/30/2024

Stephanie Holland ;

According to results from the...

08/30/2024

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology

News

Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence

04/25/2024

Stephanie Holland

According to interim analysis...

04/25/2024

Oncology

News

Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence

04/16/2024

Stephanie Holland

According to results from the...

04/16/2024

Oncology

News

Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma

03/11/2024

Allison Casey

A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.

A recent study found the use of...

03/11/2024

Oncology

News

Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma

03/11/2024

Allison Casey

According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.

According to a retrospective...

03/11/2024

Oncology

Conference Coverage

Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/27/2024

Thomas Powles , MBBS, MD;

Thomas Powles, MBBS, MD,...

01/27/2024

Oncology

Conference Coverage

Adjuvant Pembrolizumab Succeeds For Patients With Renal Cell Carcinoma At Increased Risk of Relapse

01/27/2024

Allison Casey ;

Adjuvant pembrolizumab significantly improved overall survival among patients with renal cell carcinoma at an increased risk for recurrence after surgery, when compared with placebo.

Adjuvant pembrolizumab...

01/27/2024

Oncology

Conference Coverage

Adjuvant Nivolumab Failed to Meet End Point for Patients With Renal Cell Carcinoma

01/27/2024

Allison Casey ;

In Part B of CheckMate 914,...

01/27/2024

Oncology

Conference Coverage

Subcutaneous Nivolumab Noninferior to Intravenous Administration Among Patients With Clear Cell Renal Cell Carcinoma

01/27/2024

Saby George , MD;

Saby George shares insights from...

01/27/2024

Oncology

Interactive Features

Quiz

Belzutifan vs Everolimus for Quality of Life of Patients With Advanced Clear Cell Renal Cell Carcinoma

03/21/2024

Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?

Did belzutifan improve the time...

03/21/2024

Oncology

Quiz

Quiz: Post-Surgery Everolimus for High-Risk Renal Cell Carcinoma

09/02/2022

In the phase 3 EVEREST trial which looked at everolimus after surgery in patients with high-risk renal cancer, which patients saw the greatest benefit in recurrence-free survival with everolimus?

In the phase 3 EVEREST trial...

09/02/2022

Oncology

Test Your Knowledge

Quiz: Which Study Yields Notable Benefit in Kidney Cancer?

04/15/2021

Which study reported OS results in favor of axitinib plus pembrolizumab, ultimately obtaining the lowest hazard ratio observed for survival in any phase 3 trial, a benefit seen across prognostic risk groups and regardless of PD‑L1 expression...

Which study reported OS results...

04/15/2021

Oncology

Test Your Knowledge

Quiz: Which Combo Regimen Received FDA Approval for Treatment of Advanced RCC?

02/02/2021

Which combo therapy regimen was approved by the FDA for the treatment of advanced RCC in January 2021?

Which combo therapy regimen was...

02/02/2021

Oncology

Test Your Knowledge

Quiz: Which Therapy Had Higher Safety, OS in Papillary RCC?

10/13/2020

Which therapy had a better safety profile and OS rate in the SAVOIR trial for papillary RCC?

Which therapy had a better...

10/13/2020

Oncology

Test Your Knowledge

Quiz: Is Pembrolizumab Plus Bevacizumab Beneficial for Metastatic RCC?

09/02/2020

True or False: Pembrolizumab combined with bevacizumab was proven safe and active in a study of patients with metastatic clear cell renal cell carcinoma.

True or False: Pembrolizumab...

09/02/2020

Oncology

Test Your Knowledge

Quiz: Is Ipilimumab Plus Nivolumab Active in Patients with Metastatic RCC?

07/31/2020

True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.

True or false: Ipilimumab plus...

07/31/2020

Oncology

Test Your Knowledge

Quiz: Does Nivolumab–Ipilimumab Yield Long-Term Benefit in Advanced RCC?

10/01/2019

True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.

True or False: Combining...

10/01/2019

Oncology

Recent News

News

Belzutifan Improved Survival, Response Among Patients With Advanced Clear-Cell Renal Cell Carcinoma

08/30/2024

Stephanie Holland ;

According to results from the...

08/30/2024

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology

News

Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence

04/25/2024

Stephanie Holland

According to interim analysis...

04/25/2024

Oncology

News

Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence

04/16/2024

Stephanie Holland

According to results from the...

04/16/2024

Oncology

News

Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma

03/11/2024

Allison Casey

A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.

A recent study found the use of...

03/11/2024

Oncology

News

Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma

03/11/2024

Allison Casey

According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.

According to a retrospective...

03/11/2024

Oncology

News

Belzutifan Plus Cabozantinib Shows Promise in Previously Treated Clear Cell Renal Cell Carcinoma

04/12/2023

In a phase 2 trial, belzutifan plus cabozantinib showed promising antitumor activity among patients with clear cell renal cell carcinoma who had received prior PD-1/PD-L1 inhibition.

In a phase 2 trial, belzutifan...

04/12/2023

Oncology

News

Bevacizumab Plus Sunitinib for Patients With Advanced Renal Cell Carcinoma

01/26/2023

Allison Casey ;

In a phase 1/2 study, the addition of bevacizumab to a sunitinib on/off regimen demonstrated anti-tumor activity for patients with advanced renal cell carcinoma.

In a phase 1/2 study, the...

01/26/2023

Oncology

News

Nivolumab, Ipilimumab, and Cabozantinib Triplet Therapy Demonstrates Clinical Activity for Patients With Advanced Renal Cell Carcinoma

12/01/2022

Allison Casey ;

According to results from a discontinued arm of a phase 3 trial, the immunotherapy triplet regimen of nivolumab, ipilimumab, and cabozantinib demonstrated clinical activity in previously untreated patients with advanced renal cell carcinoma.

According to results from a...

12/01/2022

Oncology

News

Frontline Axitinib Plus Pembrolizumab vs Ipilimumab Plus Nivolumab for Metastatic Renal Cell Carcinoma

10/31/2022

Findings from a comparative effectiveness analysis show no statistically significant difference in survival outcomes between axitinib plus pembrolizumab vs ipilimumab plus nivolumab for the frontline treatment of patients with metastatic...

Findings from a comparative...

10/31/2022

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology